

Preferred Drug List Announcement

MO HealthNet Division (MHD) is continuing the state-specific Preferred Drug List (PDL) evaluation process. Drugs/Drug classes for review for the upcoming quarter are identified at each of the quarterly meetings of the Drug Prior Authorization Committee.

MO HealthNet Division's clinical team will conduct the clinical reviews of the drug products under evaluation each quarter. For preferred status consideration for your product, a more detailed review request should be presented to MHD.

- All clinical information for consideration should be forwarded to Karen Powell, PharmD, MS at karen.powell@gainwelltechnologies.com. These submissions should generally follow the AMCP guideline format.
- Financial evaluations for these therapeutic class reviews are conducted by Gainwell Technologies, LLC. Companies wishing to discuss opportunities for supplemental rebates and/or the policy surrounding the PDL process should contact GWTContracting@gainwelltechnologies.com and Sandy Kapur, PharmD at sandy.kapur@gainwelltechnologies.com.
- If a public presentation is desired, please contact Carmen Burton at Carmen.M.Burton@dss.mo.gov or call (573) 751-6961.

The Drug PA Committee will convene at 10:00 a.m. on Tuesday, October 17, 2023.

Drug Therapeutic Class Name	
Cardiovascular	
<ul style="list-style-type: none"> • Angiotensin Converting Enzyme Inhibitors (ACE-Is) • ACE-Is/Diuretic Combination Agents • ACE-Is/Calcium Channel Blocker (CCB) Combination Agents • Angiotensin Receptor Blockers (ARBs) • ARB/Diuretic Combination Agents • ARB/CCB Combination Agents • ARB/CCB/Thiazide Combination Agents • ARB/Neprilysin Inhibitor Combination Agents • Anticoagulants, Injectable • Anticoagulants, Oral • Antiplatelets • Beta-blockers • Beta-blocker/Diuretic Combination Agents • CCB, Dihydropyridines • CCB, Non-dihydropyridines • Direct Renin Inhibitors & Combination Agents 	

Drug Therapeutic Class Name
<ul style="list-style-type: none"> • Lipotropics, Homozygous Familial Hypercholesterolemia (HoFH) Agents • Lipotropics, Niacin Derivatives • Lipotropics, PCSK9 Inhibitors • Lipotropics, Statins (HMG-CoA Reductase Inhibitors) & Combination Agents • Lipotropics, Triglyceride Lowering Agents • Mineralocorticoid Receptor Antagonist • Sympatholytic Agents
Central Nervous System
<ul style="list-style-type: none"> • Attention Deficit Hyperactivity Disorder (ADHD), Amphetamine-like, Long-acting • ADHD, Amphetamine-like, Short-acting • ADHD, Methylphenidate, Long-acting • ADHD, Methylphenidate, Short-acting • ADHD, Non-stimulants • Anticonvulsant, Rescue Agents • Spinal Muscular Atrophy Agents
Endocrine & Metabolic Agents
<ul style="list-style-type: none"> • Agents for Bone Ossification, Bisphosphonates • Agents for Bone Ossification, Calcitonin Agents • Antihyperuricemic Agents
Gastrointestinal
<ul style="list-style-type: none"> • Agents for Urea Cycle Disorders • Bile Salt Agents • Proton Pump Inhibitors
Ophthalmic
<ul style="list-style-type: none"> • Keratoconjunctivitis
Renal & Genitourinary
<ul style="list-style-type: none"> • Benign Prostatic Hypertrophy Inhibitors • Electrolyte Depleters, Phosphate Lowering Agents • Electrolyte Depleters, Potassium Lowering Agents
Respiratory
<ul style="list-style-type: none"> • Pulmonary Arterial Hypertension (PAH) Agents, Prostacyclins, Inhaled • PAH Agents, Prostacyclins, IV/SQ • PAH Agents, Prostacyclins, Oral • PAH Agents, Endothelin Receptor Antagonists (ETRA) • PAH Agents, Phosphodiesterase-5 Inhibitors & Soluble Guanylate Cyclase Stimulators